Cancer patients receiving their medication at leading referral hospitals across the country have been frequently experiencing ...
MedPage Today on MSN
Novel treatments for gastric cancer
Immunotherapy, targeted treatments, HIPEC, and new delivery options ...
Dennis Slamon ONCOLOGY Professor of Medicine; Chief, Division of Hematology/Oncology; Associate Director of ...
The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Background: HLX02 is the first China-manufactured trastuzumab biosimilar. Few data are currently available about HLX02 in clinical practice. This study was designed to evaluate the real-world safety ...
As researchers keep looking for ways to deescalate treatment in HER2-positive breast cancer, a trial from China looked at a chemotherapy-free regimen with endocrine therapy, a CDK4/6 inhibitor, and ...
CHICAGO — Enhertu, the antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, year by year proves more indispensable in the treatment of metastatic breast cancer. Already enmeshed in ...
Please provide your email address to receive an email when new articles are posted on . Second-line trastuzumab deruxtecan-nxki significantly improved outcomes for advanced gastric cancers compared ...
CHICAGO — AstraZeneca and Daiichi Sankyo’s targeted cancer medicine Enhertu helped participants in a late-stage clinical trial with a type of advanced gastric cancer live longer than those who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results